Ovid Therapeutics
OVID
64 hedge funds and large institutions have $163M invested in Ovid Therapeutics in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 20 reducing their positions, and 9 closing their positions.
21% more capital invested
Capital invested by funds: $135M → $163M (+$28.1M)
1.83% more ownership
Funds ownership: 58.15% → 59.98% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 69 → 64 (-5)
10% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 20
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$5.63M |
| 2 |
MAP
Madison Avenue Partners
New York
|
+$1.23M |
| 3 |
BlackRock
New York
|
+$403K |
| 4 |
State Street
Boston,
Massachusetts
|
+$296K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$242K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$1.23M |
| 2 |
TC
Tejara Capital
London,
United Kingdom
|
-$369K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$286K |
| 4 |
DA
DCF Advisers
Greenwich,
Connecticut
|
-$123K |
| 5 |
Renaissance Technologies
New York
|
-$122K |
OVID Hedge Fund Activity: Q3 2023 in Review
64 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2023, worth a combined $163M — up 21% from $135M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of OVID and 5 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 18 added.
The largest buyer was JP Morgan Chase, adding an estimated $5.63M. The largest seller was Bridgeway Capital Management, cutting an estimated $1.23M.
- 64 institutional investors held Ovid Therapeutics (OVID) as of Q3 2023, down from 69 in Q2 2023.
- Funds reported $163M of Ovid Therapeutics stock for Q3 2023, up 21% quarter-over-quarter.
- 5 funds opened new Ovid Therapeutics positions in Q3 2023 and 9 closed out, a net change of -4 holders.
- The largest Ovid Therapeutics buyer in Q3 2023 was JP Morgan Chase, an estimated $5.63M added.
- The largest Ovid Therapeutics seller in Q3 2023 was Bridgeway Capital Management, an estimated $1.23M sold.
Based on aggregated 13F filings for Q3 2023.